Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Context Therapeutics Inc. - Common Stock (NQ: CNTX ) 1.140 -0.010 (-0.87%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Context Therapeutics Inc. - Common Stock < Previous 1 2 Next > Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results November 06, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics to Participate in Upcoming Investor Conferences in November October 23, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting October 16, 2024 From Context Therapeutics Inc. Via GlobeNewswire BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody September 23, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors September 04, 2024 The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results August 07, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations August 01, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 July 10, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Reports First Quarter 2024 Operating and Financial Results May 08, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 May 02, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Announces $100 Million Private Placement May 02, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers April 01, 2024 Important Regulatory Milestone Supports Next Phase of CTIM-76 Development From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Reports Full Year 2023 Operating and Financial Results March 21, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results November 09, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 October 31, 2023 From Context Therapeutics Inc. Via GlobeNewswire 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis October 23, 2023 Via ACCESSWIRE Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting September 27, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update August 10, 2023 Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76. Via TheNewswire.com Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results August 09, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics to Participate in Two August 2023 Investor Conferences August 01, 2023 From Context Therapeutics Inc. Via GlobeNewswire Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN June 05, 2023 Via AB Newswire Context Therapeutics Reports First Quarter 2023 Operating and Financial Results May 10, 2023 From Context Therapeutics Inc. Via GlobeNewswire Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference April 18, 2023 Via ACCESSWIRE Context Therapeutics to Participate in Two April 2023 Investor Conferences April 03, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates March 22, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 March 15, 2023 Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer February 06, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer January 31, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers January 09, 2023 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones January 04, 2023 From Context Therapeutics Inc. Via GlobeNewswire < Previous 1 2 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
